Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eli M Roth

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|November 2, 2012
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemiaEli M Roth, James M McKenney, Corinne Hanotin, et al.
European Heart Journal|January 26, 2010
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trialEvan A Stein, Eli M Roth, James M Rhyne, et al.
Postgraduate Medicine|January 23, 2015
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysisMichael J Koren, Eli M Roth, James M McKenney, et al.
Journal of Cardiovascular Pharmacology|July 15, 2009
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjectsEli M Roth, Harold E Bays, Alan D Forker, et al.
Atherosclerosis|September 19, 2016
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE IEli M Roth, Patrick M Moriarty, Jean Bergeron, et al.
Journal of Clinical Lipidology|January 15, 2013
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studiesEli M Roth, Robert S Rosenson, Peter H Jones, et al.
Diabetes Care|June 25, 2010
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemiaHarold E Bays, Eli M Roth, James M McKenney, et al.
The Annals of Pharmacotherapy|October 2, 2008
Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation TrialRobert A Kloner, Joel Neutel, Eli M Roth, et al.
Clinical Drug Investigation|December 10, 2009
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension studyMark S Kipnes, Eli M Roth, James M Rhyne, et al.
Clinical Therapeutics|September 4, 2013
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)Kevin C Maki, David G Orloff, Stephen J Nicholls, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|November 2, 2012
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemiaEli M Roth, James M McKenney, Corinne Hanotin, et al.
European Heart Journal|January 26, 2010
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trialEvan A Stein, Eli M Roth, James M Rhyne, et al.
Postgraduate Medicine|January 23, 2015
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysisMichael J Koren, Eli M Roth, James M McKenney, et al.
Journal of Cardiovascular Pharmacology|July 15, 2009
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjectsEli M Roth, Harold E Bays, Alan D Forker, et al.
Atherosclerosis|September 19, 2016
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE IEli M Roth, Patrick M Moriarty, Jean Bergeron, et al.
Journal of Clinical Lipidology|January 15, 2013
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studiesEli M Roth, Robert S Rosenson, Peter H Jones, et al.
Diabetes Care|June 25, 2010
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemiaHarold E Bays, Eli M Roth, James M McKenney, et al.
The Annals of Pharmacotherapy|October 2, 2008
Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation TrialRobert A Kloner, Joel Neutel, Eli M Roth, et al.
Clinical Drug Investigation|December 10, 2009
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension studyMark S Kipnes, Eli M Roth, James M Rhyne, et al.
Clinical Therapeutics|September 4, 2013
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)Kevin C Maki, David G Orloff, Stephen J Nicholls, et al.
Pageof 4